Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Equipment >

Ekso Bionics Holdings, Inc. (EKSO)

Add EKSO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, skepticone, Rhetorical
Search This Board: 
Last Post: 8/22/2017 8:36:52 PM - Followers: 85 - Board type: Free - Posts Today: 0

Industry leaders in healthcare, military, and industrial exoskeletons 
                                         (Continue below to message board)                                  


Ekso GT (Healthcare):

Ekso GT is a robotic exoskeleton used for over-ground gait training in people with a neurological diagnosis. It helps patients re-learn the correct step patterns and weight shifts involved in walking, potentially mitigating compensatory behaviors.

Ekso GT’s Variable Assist software allows physical therapists to determine how much power is provided to either side of the person’s body. This balances the physical effort that the person exerts with the amount of help that he or she needs to achieve a more normalized gait. It also makes the device suitable for a broad spectrum of neuro-rehabilitation activities and keeps individuals challenged as they progress through their rehabilitation.

For people who thought they would never stand or walk again, Ekso GT provides hope for greater mobility and independence.

[Christina Kwasnica, M.D., medical director for the Barrow Neuro Rehabilitation Center, notes, “The robotic device allows us to get patients up on their feet earlier. The gains we see are overwhelming and the positive effects on a patient’s mood and motivation is unbelievable.”

Ekso Bionics(TM) Receives Its First NIH Grant (Oct 28, 2014):
RICHMOND, Calif., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that it has been awarded a P20 Exploratory Grant from the National Institutes of Health (NIH) to continue the development of an exoskeleton prototype for children. This work will be done in collaboration with the pediatric rehabilitation department at the UCSF Benioff Children's Hospital Oakland and will consist of Ekso Bionics developing a pediatric version of its Ekso GT™ robotic exoskeleton. Working with UCSF Benioff Children's Hospital Oakland allows for the effective integration of advanced robotics into a world-class pediatric rehabilitative practice.

Ekso Bionics Licences Intellectual Property to Ottobock (Nov 3, 2014):

Ekso GT™ Robotic Exoskeleton Cleared by FDA for Use With Stroke and Spinal Cord Injury Patients (Apr 4, 2016):

EKSO Bionics Robotic Exoskeletons Gain Global Connectivity With Vodafone IoT Technology (Jun 7, 2016):

Ekso Bionics® Launches Smart Assist (Oct 4, 2016):

Ekso Bionics® Launches EksoPulse Cloud-Based Analytics (Feb 9, 2017):

Ekso Bionics and Vodafone Receive 2016 HealthTechZone Telehealth Award (Apr 7, 2017):

Ekso: T.A.L.O.S. & Warrior Web (D.O.D.):

T.A.L.O.S. (Tactical Assault LIght Operator Suit):
Ekso Labs was awarded an Other Transaction for Prototypes Agreement from U.S. Special Operations Command (SOCOM) to develop technologies for their Tactical Assault Light Operator Suit (TALOS) project. TALOS is a futuristic assault suit that promises to provide superhuman strength with superior mobility and protection, and is often referred to as the "Iron Man" suit. The exoskeleton chassis, which Ekso Labs is developing, will be designed to allow soldiers to carry out their mission with agility, while carrying hundreds of pounds of load. The TALOS project is integrating other functional elements, including armor and systems, to provide situational awareness and technology for vital signs monitoring.

Ekso Bionics(TM) Secures Second Phase of U.S. Special Operation Command's TALOS Project

Ekso(TM) Labs Secures Third Contract With the U.S. Special Operations Command (SOCOM) for Upper Extremity TALOS Project (5/20/15)

Warrior Web Flexible Exoskeleton:
Ekso Bionics™ Selected for Development of Next-Generation DARPA Exoskeleton

Warrior Web A:
Testing for the Warrior Web Task A project culminated last week with six soldiers marching through 84 miles of obstacle filled terrain, carrying large loads, weapon and helmet. There were no incidences of failure reported.

Warrior Web B:

"Ekso Bionics (NASDAQ: EKSO), having successfully supplied technology to Warrior Web Task A, has been selected to participate in the second and concluding Warrior Web Task B.

Ekso Bionics will gain $4.5 million in the combined contract for both tasks." - RBR

Army R&D with RE2 Robotics:
(This is from a press release from RE2, not from Ekso Bionics. Ekso is simply jointly involved as mentioned below)
Note: EKSO is now on the NASDAQ exchange not the OTCBB

"The goal of the Phase II effort is to develop a simulation tool capable of producing validated biomechanical data on muscle forces, stresses, joint loads, and metabolic load that a human subject would have produced during load carriage with and without the use of a robotic exoskeleton. This data will help the Army analyze the benefits of exoskeletons and develop injury predictions.

“By directly modeling the interaction between a human user and the exoskeleton, our simulator will help to identify potential injury mechanisms and issues before any large-scale deployment of the device – ultimately reducing injuries while saving the Army time and money,” stated Jorgen Pedersen, president and CEO for RE2.

RE2 is partnering with biomechanical exoskeleton experts at Ekso Bionics™ (OTCBB: EKSO), neuromusculoskeletal simulation leader, Dr. Scott Delp and Dr. Jennifer Hicks, faculty at Stanford University, and the Human Engineering Research Laboratories at the University of Pittsburgh to design and test the Biomechanical Exoskeleton Simulator System."


EksoZeroG and Artemis (Construction/Tool Usage):


Ekso Bionics has spent several years designing and perfecting a range of ergonomic tool arms which are used to weightlessly manoeuvre heavy tools. These arms rely on spring tension and innovative design to balance the weight of tools used in drilling, sanding, riveting and many other applications. The Ekso Bionics Zero G arms are designed to hold loads of up to 19kg and fully balance the weight thus allowing the user to freely, safely and accurately manoeuvre the load in any direction without injury or fatigue.

The ergonomic tool arms have a variety of mounting options to suit the application including portable gantry’s, carts, jib arms, and linear rail. These systems require very little maintenance, no expensive inputs like electricity or compressed air, and have already been successfully used in a variety of industries from aerospace and defence to automotive manufacturing.

  • -Payback of less than a year
    -ROI of 100%
    -Less than 30 min of operator training required to achieve competency
    -No expensive inputs such as electricity or air required
    -Very minimal maintenance
    -Modular design for flexibility
    -13 different mobile and fixed mounting options
    -4 different arm configurations

There are several mounting options fro the Zero G ergonomic tool arms from ground based trolleys, to gantry mounts, jib crane mounts, linear rail and bench top mounting.

The Zero G ergonomic tool arm is used extensively in the aerospace,construction, mining and ship building industries in a range of roles. The weight balancing aspect of the Equipois Zero G system allows workers to grind, drill, chip surfaces easily for long periods of time even if the surface is in an overhead orientation.

Current users of the Equipois Zero G system include Airbus, Boeing, General Electric, BHP Billiton, Gammon Construction, Lockheed Martin, Chrysler, Ford, Honda, Nissan, Toyota, Caterpillar, John Deere, Bradken and many more.


Ekso Artemis:

"RICHMOND, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an exoskeleton company, today announced that it has completed the development of a lightweight, flexible load carriage exoskeleton prototype named Artemis."

Ekso Bionics at a Glance:
-Founded in 2005 and headquartered in Richmond, CA 
--Originally Berkely Bionics of Univsity of California, Berkeley
-The current CEO is Thomas Loobyy
-Ekso is the industry leader in healthcare, military, and industrial exoskeletons
-The Ekso Bionics Ekso GT™ is the first and only FDA approved exoskeleton for stroke rehabiliation
-Over 190 international patent cases (granted or pending)

-Headquartered in the historic Ford Motor Company Assembly Plant, the largest wartime production assembly plant to be built on the West Coast
Company Presentation:

*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
Do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested. There are no guarantees when buying or selling any security.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
EKSO News: Statement of Changes in Beneficial Ownership (4) 08/18/2017 05:01:21 PM
EKSO News: Current Report Filing (8-k) 08/17/2017 05:29:32 PM
EKSO News: Statement of Changes in Beneficial Ownership (4) 08/15/2017 06:39:22 PM
EKSO News: Ekso BionicsĀ® Announces Commencement of $34 Million Rights Offering 08/14/2017 08:46:52 AM
EKSO News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 08/14/2017 08:36:30 AM
#2381  Sticky Note On Talos: [continued "top level support" for the Rhetorical 08/16/16 07:02:33 PM
#1234  Sticky Note $EKSO recent news/filings RECENT NEWS 02-03-16 1 MIL. GRANT mick 02/04/16 11:05:48 AM
#3701   email from Scottrade today berta 08/22/17 08:36:52 PM
#3700   Just got off the phone with Ameritrade re-organisation skepticone 08/22/17 11:32:18 AM
#3699   Just got off the phone with my accountant, skepticone 08/22/17 11:02:34 AM
#3698   I do not. kpisme 08/22/17 10:59:08 AM
#3697   The question I just raised does not apply skepticone 08/22/17 10:06:45 AM
#3696   @kpisme...Do you know how they treat the sale skepticone 08/22/17 09:42:45 AM
#3695   Yes, all of mine, please over subscribed for kpisme 08/22/17 09:27:17 AM
#3694   Thanks Skep Dalcan 08/22/17 09:24:52 AM
#3693   @Dalcan...See post #3680 skepticone 08/22/17 08:45:35 AM
#3692 skepticone 08/22/17 08:43:31 AM
#3691   Has anyone been able to purchase any shares Dalcan 08/22/17 08:39:47 AM
#3690   Stock price keeps declining. Guess no one thinks radly 08/21/17 03:46:54 PM
#3688   "I think it's good we're loosing money right Rhetorical 08/20/17 01:48:56 AM
#3687 skepticone 08/19/17 09:08:56 PM
#3686   MAYBE U SHOULD APPLY to there PR DEPT berta 08/18/17 09:27:45 PM
#3685   NICE berta 08/18/17 09:24:28 PM
#3684   I've seen a lot of zero-g videos (most Rhetorical 08/18/17 06:19:26 PM
#3683 Steve Brown with Ekso ZeroG Rhetorical 08/18/17 05:35:11 PM
#3682   It may just be a timing issue. There skepticone 08/18/17 10:26:15 AM
#3681   Was just told by e trade that I Billyp54 08/18/17 09:49:15 AM
#3680   Just finished speaking with Ameritrade and have exercised skepticone 08/18/17 09:25:10 AM
#3679   CHECK YOUR STOCK ACCOUNT...My CUSIP# has appeared on skepticone 08/17/17 09:02:55 PM
#3678 skepticone 08/17/17 08:57:11 PM
#3677   Thank you. Thats what i learned here in Germany Stecker 08/17/17 07:26:00 PM
#3676   I think your comment was spot on because Rhetorical 08/17/17 07:13:52 PM
#3675   Same Here....Waiting for a CUSIP# to appear in wildwertski 08/17/17 06:33:39 PM
#3674   Not yet, I was told that it would skepticone 08/16/17 02:53:12 PM
#3673   Has anyone received their subscription notification via mail ElmerJFudd 08/16/17 12:31:59 PM
#3672   Very good video. Very interesting. wildwertski 08/16/17 12:22:02 PM
#3671   See post #3656 skepticone 08/16/17 09:55:21 AM
#3670   That is the reasoning I brought up in skepticone 08/16/17 09:52:53 AM
#3669   That is not always the case. I don't skepticone 08/16/17 09:42:58 AM
#3668   Selling after record date: Sell for 1,60 Buy back for 1 Stecker 08/16/17 09:18:45 AM
#3667   Probably because rights offerings are not good and golfblues 08/16/17 08:07:55 AM
#3666   Angold began selling 221,000+ shares the day after skepticone 08/15/17 09:40:33 PM
#3665   This can be found on the EKSO Facebook page skepticone 08/15/17 01:47:26 PM
#3664 This is the first part of the prospe Rhetorical 08/14/17 02:02:00 PM
#3663   MAKE SURE YOU READ THE PROSPECTUS THAT HAS skepticone 08/14/17 08:56:59 AM
#3662   Ekso Bionics® Announces Commencement of $34 Million Rights Offering mvan13 08/14/17 08:56:09 AM
#3661   From Keith Fitz-gerald skepticone 08/14/17 08:44:10 AM
#3660 skepticone 08/13/17 08:34:44 PM
#3659   yes sounds correct the agent berta 08/11/17 09:23:21 PM
#3658   In the conference call it was said that skepticone 08/11/17 06:14:39 PM
#3657   skeptic my guess you are very berta 08/11/17 03:54:50 PM
#3656   I have a question for any of you skepticone 08/11/17 03:29:12 PM
#3655 skepticone 08/10/17 09:01:23 AM
#3654 Rhetorical 08/10/17 12:31:07 AM
#3653 only sort of related based on sensors Rhetorical 08/09/17 12:24:05 PM
#3652 Stecker 08/09/17 08:08:13 AM
#3651   The institutions that barely hold any shares aren't Rhetorical 08/08/17 06:22:13 PM